Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 FasT CAR-T in B-cell NHL
NCT04638270Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC007F in B-cell non-Hodgkin lymphoma, sponsored by Xinqiao Hospital. Primary endpoints: Measurable lesion size at 4 weeks, Standardized Uptake Value at 4 weeks and 1 more. Status: unknown.
02
Drugs
GC007F
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04638270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638270.